LOS ANGELES — This city is now home to its very first biotech venture firm: Dr. Beth Seidenberg, a general partner at Kleiner Perkins, will now be heading up a $320 million fund called Westlake Village BioPartners dedicated exclusively to the life sciences — and, potentially, helping build up the LA area as a new biotech hub.

Seidenberg, former chief medical officer of Amgen, is bringing on board Sean Harper — who by January will end his tenure as R&D head at the Los Angeles-area biotech. Some of the better-known companies in Seidenberg’s portfolio include ovarian cancer therapeutics company Tesaro, allogeneic T cell company Atara Biotherapeutics, and epigenetics player Epizyme.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy